FDA Approves Akorn's Ofloxacin Ophthalmic Solution
Posted on: Thursday, 17 April 2008, 03:00 CDT
Specialty pharmaceutical firm Akorn has announced that the FDA has granted approval for the company's abbreviated new drug application for ofloxacin ophthalmic solution USP, 0.3%.
Ofloxacin ophthalmic solution is an anti-infective used to treat infections caused by bacteria in conjunctivitis and corneal ulcers.
Arthur Przybyl, Akorn's president and CEO, said: "This product will be manufactured in our Decatur, Illinois facility, and represents an important addition to our ophthalmic product line. We expect to launch Ofloxacin in the third quarter of 2008."
Source: Datamonitor
Related Articles
- FDC Wins Approval for Ciprofloxacin Ophthalmic Solution
- Hi-Tech Pharmacal Receives Final Approval for Ofloxacin Otic Solution
- Alcon's Eye Allergy Drug, PATANOL(R) Ophthalmic Solution, Approved in Japan
- Acuity Pharmaceuticals Enters Agreement to Develop Anti-Inflammatory siRNA for Ophthalmic Uses
- Novagali Pharma Completes EUR26 Million Financing to Support Phase III Clinical Trials and Development of New Ophthalmic Products
- Big Shares Sale for Ophthalmic
- Bausch & Lomb Teams With Novartis Ophthalmics To Co-Promote Bausch & Lomb Retisert(TM)
- Apotex Receives Final Approval for Ofloxacin Otic 0.3%
- New Diamond Ophthalmic Knife Incorporating 'LuerLock'
Rating: 2.7 / 5 (7 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds